Your shopping cart is currently empty

ZZ7-23-022 (ZZ7) is a selective molecular glue degrader targeting BRD9. It effectively degrades BRD9 in synovial sarcoma cells without affecting cardiac cells and is applicable in cancer research.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | ZZ7-23-022 (ZZ7) is a selective molecular glue degrader targeting BRD9. It effectively degrades BRD9 in synovial sarcoma cells without affecting cardiac cells and is applicable in cancer research. |
| In vitro | ZZ7-23-022 (0.1-3 μM, 5 h) induces dose-dependent degradation of BRD9 in Jurkat cells. Furthermore, ZZ7 (0.05-0.5 μM, 5 h) effectively degrades BRD9 in synovial sarcoma cells (CME-1, HS-SY-II, 1273/99), while having no effect on cardiomyocytes. However, ZZ7 (0.1-3 μM, 5 h) does not degrade BRD9 in DCAF16-knockout Jurkat/K-562 cells, and it also loses degradation activity in DCAF16-Cys178 mutant cells. |
| Synonyms | ZZ7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.